The emerging role of cannabinoid neuromodulators in symptom management

Mellar Davis; Vincent Maida; Paul Daeninck; Joseph Pergolizzi

doi:10.1007/s00520-006-0180-0

The emerging role of cannabinoid neuromodulators in symptom management

Mellar Davis, Vincent Maida, Paul Daeninck, Joseph Pergolizzi

School of Medicine

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

Introduction: The cannabinoids nabilone (Cesamet) and dronabinol (Marinol) are indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in cancer patients who have failed to respond adequately to conventional antiemetic therapy. Discussion: The endocannabinoid (CB) system interacts with numerous other systems and pharmaceutical cannabinoids target ubiquitous CB1 and CB2 receptors in the central nervous system and periphery, relieving nausea and vomiting and pain. Summary: The benefits of this novel class of medications in cancer may extend beyond CINV, as indicated by data from preclinical studies and animal models.

Original language	English (US)
Pages (from-to)	63-71
Number of pages	9
Journal	Supportive Care in Cancer
Volume	15
Issue number	1
DOIs	https://doi.org/10.1007/s00520-006-0180-0
State	Published - Jan 2007

Keywords

Cannabinoids
CB1 and CB2 receptors
Chemotherapy-induced nausea and vomiting
Pain

ASJC Scopus subject areas

Oncology
General Nursing

Access to Document

10.1007/s00520-006-0180-0

Cite this

@article{1726a166bfd049ebbf1ec4aa2efb8981,

title = "The emerging role of cannabinoid neuromodulators in symptom management",

abstract = "Introduction: The cannabinoids nabilone (Cesamet) and dronabinol (Marinol) are indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in cancer patients who have failed to respond adequately to conventional antiemetic therapy. Discussion: The endocannabinoid (CB) system interacts with numerous other systems and pharmaceutical cannabinoids target ubiquitous CB1 and CB2 receptors in the central nervous system and periphery, relieving nausea and vomiting and pain. Summary: The benefits of this novel class of medications in cancer may extend beyond CINV, as indicated by data from preclinical studies and animal models.",

keywords = "Cannabinoids, CB1 and CB2 receptors, Chemotherapy-induced nausea and vomiting, Pain",

author = "Mellar Davis and Vincent Maida and Paul Daeninck and Joseph Pergolizzi",

year = "2007",

month = jan,

doi = "10.1007/s00520-006-0180-0",

language = "English (US)",

volume = "15",

pages = "63--71",

journal = "Supportive Care in Cancer",

issn = "0941-4355",

publisher = "Springer Verlag",

number = "1",

}

TY - JOUR

T1 - The emerging role of cannabinoid neuromodulators in symptom management

AU - Davis, Mellar

AU - Maida, Vincent

AU - Daeninck, Paul

AU - Pergolizzi, Joseph

PY - 2007/1

Y1 - 2007/1

N2 - Introduction: The cannabinoids nabilone (Cesamet) and dronabinol (Marinol) are indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in cancer patients who have failed to respond adequately to conventional antiemetic therapy. Discussion: The endocannabinoid (CB) system interacts with numerous other systems and pharmaceutical cannabinoids target ubiquitous CB1 and CB2 receptors in the central nervous system and periphery, relieving nausea and vomiting and pain. Summary: The benefits of this novel class of medications in cancer may extend beyond CINV, as indicated by data from preclinical studies and animal models.

AB - Introduction: The cannabinoids nabilone (Cesamet) and dronabinol (Marinol) are indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in cancer patients who have failed to respond adequately to conventional antiemetic therapy. Discussion: The endocannabinoid (CB) system interacts with numerous other systems and pharmaceutical cannabinoids target ubiquitous CB1 and CB2 receptors in the central nervous system and periphery, relieving nausea and vomiting and pain. Summary: The benefits of this novel class of medications in cancer may extend beyond CINV, as indicated by data from preclinical studies and animal models.

KW - Cannabinoids

KW - CB1 and CB2 receptors

KW - Chemotherapy-induced nausea and vomiting

KW - Pain

UR - http://www.scopus.com/inward/record.url?scp=33846174632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846174632&partnerID=8YFLogxK

U2 - 10.1007/s00520-006-0180-0

DO - 10.1007/s00520-006-0180-0

M3 - Article

C2 - 17139494

AN - SCOPUS:33846174632

SN - 0941-4355

VL - 15

SP - 63

EP - 71

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

IS - 1

ER -

The emerging role of cannabinoid neuromodulators in symptom management

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this